Jonathan Freve joins Galecto as Chief Financial Officer
pharmafile | May 5, 2020 | Appointment | Manufacturing and Production |
The biotech company Galecto Inc have appointed Jonathan Freve as its Chief Financial Officer, and in his role he will lead financial operations including overseeing investor relations and fundraising efforts.
Hans Schambye, CEO of Galecto, commented on the appointment and said: “I am delighted to welcome Jon Freve as our new CFO, as he has clearly demonstrated his ability to build and grow successful finance organizations. His expertise, particularly related to private and public company financing strategies, is a very good match for Galecto’s stage of development. Galecto is entering an exciting time as we pursue our ambitious targets in progressing GB0139 towards market and exploring the exciting potential of our clinical stage pipeline targeting fibrosis and cancer.”
Freve was previously the CFO and Treasurer at Spring Bank Pharmaceuticals, and prior to this he was the Senior Director of Finance at Santaris Pharma. He began his career at the Financial Accounting Standards Board and PricewaterhouseCoopers, where he worked in audit and transaction services.
In terms of education, Freve holds a Bachelor’s degree in Business Administration from the University of Massachusettes Amherst. He replaces Jakob Dynnes Hanson who will remain as an advisor.